koto_feja/E+ via Getty Images
- Revolution Medicines (NASDAQ:RVMD) and Summit Therapeutics (NASDAQ:SMMT) announced a clinical partnership to assess each of Revolution's RAS(ON) inhibitors with Summit's bispecific antibody, ivonescimab, in various solid tumor settings.
- The partnership will assess Revolution's multi-selective inhibitor daraxonrasib, G12D-selective inhibitor zoldonrasib and G12C-selective inhibitor elironrasib with ivonescimab.
More on Summit Therapeutics, Revolution Medicines
- Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History
- Explaining Summit's Fall Despite Positive Data In EGFR-Positive Lung Cancer
- Summit Therapeutics: Market Overreaction Creates Opportunity
- Revolution Medicines dips 5%, gets $2B flexible funding
- Revolution Medicines gets FDA Breakthrough Therapy status for daraxonrasib